Serum Albumin, Globulin and Albumin–Globulin Ratios as Biomarkers of Clinical Outcomes in COVID-19 Pneumonia
Rauno Joks, Tamar Smith-Norowitz, Shawn Mathew, Mansi R. Kothari, Sairaman Nagarajan · 2026
Read Serum Albumin, Globulin and Albumin–Globulin Ratios as Biomarkers of Clinical Outcomes in COVID-19 Pneumonia by Rauno Joks, Tamar Smith-Norowitz, Shawn Mathew, Mansi R. Kothari, Sairaman Nagarajan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13302725.txt.
Description
Routine protein levels sketch a COVID-19 patient's road ahead, Rauno Joks and colleagues report in a 2026 chart review. Of 569 adults hospitalized with COVID-19 pneumonia, sixty had the full laboratory and immune data the analysis required. Albumin, globulin, and their ratio were tested against comorbidity burden, predicted ten-year survival, severity scores, and length of stay.
Low albumin and a low albumin-to-globulin ratio each tracked with heavier comorbidity, lower predicted survival, and longer hospitalization, independent of other factors. Falling total protein meant higher severity scores. Globulin alone predicted nothing. The authors propose these cheap, standard tests as aids for sorting patients by likely course and recovery.
Catalog record
| CREATOR | Rauno Joks, Tamar Smith-Norowitz, Shawn Mathew, Mansi R. Kothari, Sairaman Nagarajan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29472 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |